Price T Rowe Associates Inc. MD cut its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) by 29.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,079,742 shares of the company’s stock after selling 1,254,941 shares during the period. Price T Rowe Associates Inc. MD owned 10.30% of RAPT Therapeutics worth $74,099,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. Great West Life Assurance Co. Can purchased a new position in RAPT Therapeutics in the 3rd quarter valued at $28,000. Quantbot Technologies LP purchased a new position in shares of RAPT Therapeutics in the second quarter worth about $107,000. SG Americas Securities LLC acquired a new position in RAPT Therapeutics during the third quarter worth about $153,000. Ensign Peak Advisors Inc boosted its position in RAPT Therapeutics by 40.1% during the third quarter. Ensign Peak Advisors Inc now owns 6,740 shares of the company’s stock worth $162,000 after acquiring an additional 1,930 shares during the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in RAPT Therapeutics by 37.0% during the 2nd quarter. Virtus ETF Advisers LLC now owns 6,964 shares of the company’s stock valued at $127,000 after acquiring an additional 1,882 shares in the last quarter.
Insiders Place Their Bets
In other RAPT Therapeutics news, insider William Ho sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 24th. The stock was sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the sale, the insider now owns 30,072 shares of the company’s stock, valued at $902,160. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders sold a total of 15,742 shares of company stock valued at $384,252 over the last quarter. 5.00% of the stock is owned by insiders.
RAPT Therapeutics Price Performance
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on the company. The Goldman Sachs Group initiated coverage on RAPT Therapeutics in a report on Thursday, December 1st. They set a “buy” rating and a $27.00 target price on the stock. HC Wainwright reduced their price objective on RAPT Therapeutics from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, November 14th. Guggenheim assumed coverage on RAPT Therapeutics in a research report on Wednesday, January 4th. They set a “buy” rating and a $55.00 price objective on the stock. Piper Sandler reduced their price objective on RAPT Therapeutics from $34.00 to $33.00 in a research report on Thursday, December 8th. Finally, Wells Fargo & Company reduced their price objective on RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 4th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $44.14.
RAPT Therapeutics Company Profile
Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.
- Get a free copy of the StockNews.com research report on RAPT Therapeutics (RAPT)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.